Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides:: the high-mannose, hybrid, and complex types

被引:293
作者
Kanda, Yutaka [1 ]
Yamada, Tsuyoshi [1 ]
Mori, Katsuhiro [1 ]
Okazaki, Akira [1 ]
Inoue, Miho [1 ]
Kitajima-Miyama, Kazuko [1 ]
Kuni-Kamochi, Reiko [1 ]
Nakano, Ryosuke [1 ]
Yano, Keiichi [1 ]
Kakita, Shingo [1 ]
Shitara, Kenya [1 ]
Satoh, Mitsuo [1 ]
机构
[1] Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan
关键词
antibody effector functions; Fc oligosaccharides; IgG1 lacking core-fucosylation; N-linked oligosaccharide structure; pharmacokinetics;
D O I
10.1093/glycob/cwl057
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The structure of asparagine-linked oligosaccharides attached to the antibody constant region (Fc) of human immunoglobulin G1 (IgG1) has been shown to affect the pharmacokinetics and antibody effector functions of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, it is still unclear how differences in the N-linked oligosaccharide structures impact the biological activities of antibodies, especially those lacking core fucose. Here, we succeeded in generating core fucose-lacking human IgG1 antibodies with three different N-linked Fc oligosaccharides, namely, a high-mannose, hybrid, and complex type, using the same producing clone, and compared their activities. Cultivation of an alpha-1,6-fucosyltransferase (FUT8) knockout Chinese hamster ovary cell line in the presence or absence of a glycosidase inhibitor (either swainsonine or kifunensine) yielded antibody production of each of the three types without contamination by the others. Two of three types of nonnaturally occurring atypical oligosaccharide IgG1, except the complex type, reduced the affinity for both human lymphocyte receptor IIIa (Fc gamma RIIIa) and the C1q component of the complement, resulting in reduction of ADCC and CDC. The bulky structure of the nonreducing end of N-linked Fc oligosaccharides is considered to contribute the CDC change, whereas the structural change in the reducing end, i.e. the removal of core fucose, causes ADCC enhancement through improved Fc gamma RIIIa binding. In the pharmacokinetic profile, although no significant difference of human neonatal Fc receptor (FcRn)-binding affinity was observed among the three types, the complex type showed longer serum half-lives than the other types irrespective of core fucosylation in mice, which also suggests the contribution of the nonreducing end structure. The present study provides basic information on the effects of core fucose-lacking N-linked Fc oligosaccharides on antibody biological activities.
引用
收藏
页码:104 / 118
页数:15
相关论文
共 48 条
[1]  
AWWAD M, 1994, CANCER IMMUNOL IMMUN, V38, P23, DOI 10.1007/s002620050030
[2]   Inhibition of hybrid-and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway [J].
Crispin, Max ;
Harvey, David J. ;
Chang, Veronica T. ;
Yu, Chao ;
Aricescu, A. Radu ;
Jones, E. Yvonne ;
Davis, Simon J. ;
Dwek, Raymond A. ;
Rudd, Pauline M. .
GLYCOBIOLOGY, 2006, 16 (08) :748-756
[3]   The carbohydrate at FcγRIIIa Asn-162 -: an element required for high affinity binding to non-fucosylated IgG glycoforms [J].
Ferrara, C ;
Stuart, F ;
Sondermann, P ;
Brükner, P ;
Umaña, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (08) :5032-5036
[4]   Modulation of therapeutic antibody effector functions by glycosylation engineering:: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II [J].
Ferrara, C ;
Brünker, P ;
Suter, T ;
Moser, S ;
Püntener, U ;
Umaña, P .
BIOTECHNOLOGY AND BIOENGINEERING, 2006, 93 (05) :851-861
[5]   SYSTEMATIC FRACTIONATION OF OLIGOSACCHARIDES OF HUMAN IMMUNOGLOBULIN-G BY SERIAL AFFINITY-CHROMATOGRAPHY ON IMMOBILIZED LECTIN COLUMNS [J].
HARADA, H ;
KAMEI, M ;
TOKUMOTO, Y ;
YUI, S ;
KOYAMA, F ;
KOCHIBE, N ;
ENDO, T ;
KOBATA, A .
ANALYTICAL BIOCHEMISTRY, 1987, 164 (02) :374-381
[6]   Crystallographic structure of an intact IgG1 monoclonal antibody [J].
Harris, LJ ;
Skaletsky, E ;
McPherson, A .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 275 (05) :861-872
[7]   CRYSTALLOGRAPHIC STRUCTURE STUDIES OF AN IGG MOLECULE AND AN FC FRAGMENT [J].
HUBER, R ;
DEISENHOFER, J ;
COLMAN, PM ;
MATSUSHIMA, M ;
PALM, W .
NATURE, 1976, 264 (5585) :415-420
[8]   Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin g on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa [J].
Iida, S ;
Misaka, H ;
Inoue, M ;
Shibata, M ;
Nakano, R ;
Yamane-Ohnuki, N ;
Wakitani, M ;
Yano, K ;
Shitara, K ;
Satoh, M .
CLINICAL CANCER RESEARCH, 2006, 12 (09) :2879-2887
[9]   Interaction sites on human IgG-Fc for FcγR:: current models [J].
Jefferis, R ;
Lund, J .
IMMUNOLOGY LETTERS, 2002, 82 (1-2) :57-65
[10]   Glycosylation of recombinant antibody therapeutics [J].
Jefferis, R .
BIOTECHNOLOGY PROGRESS, 2005, 21 (01) :11-16